
CLAIMS

1. A compound of formula (IA) or a pharmaceutically acceptable salt thereof




(IA)

for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

2. The compound for use according to claim 1, for use in the treatment of the hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome and tardive dyskinesia.

3. A compound of formula (IA) or a pharmaceutically acceptable salt thereof



(IA)

for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome and restless leg syndrome.


4. The compound for use according to any of the claims 1-3, wherein said prophylaxis or treatment comprises administering as a unique active ingredient the compound of formula (IA).

5. The compound for use according to any of the claims 1-4, wherein said prophylaxis or treatment comprises administering the compound of formula (IA) in combination therapy with an additional therapeutic agent selected from

the group consisting of a compound of formula (IB), a compound of formula (IC), a neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof;


wherein:

the compound of formula (IB) is



(IB)

and the compound of formula (IC) is



(IC)

6. The compound for use according to claim 5, wherein the combination therapy comprises administering to a subject simultaneously, sequentially or separately the compound of formula (IA) and the additional therapeutic agent.

7. The compound for use according to any of the claims 5 or 6, wherein the additional therapeutic agent is selected from the group consisting of a compound of formula (IB), a compound of formula (IC), amantadine, riluzole, tetrabenazine, reserpine, and donepezil.

8. A combination of a compound of formula (IA) and an additional therapeutic agent as defined in any of the claims 5-7, for use in the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

9. A combination of a compound of formula (IA) and an additional therapeutic agent as defined in any of the claims 5-8, for use in the prophylaxis and/or

treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, and restless leg syndrome.

10. The compound for use according to any of the claims 1-9, wherein the hyperkinetic movement disorder is selected from the group consisting of abdominal dyskinesias, akathisic movements, asynergia, ataxia, athetosis, ballism, chorea, dysmetria, dystonia, hemifacial spasm, hyperekplexia, hypnogenic dyskinesias, jumpy stumps, moving toes and/or fingers, myoclonus, myokymia, myorhythmia, paroxysmal dyskinesias, tics, and tremors.

11. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia.

12. The compound for use according to any of the claims 1-11, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease.

13. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is tics associated to Tourette syndrome and tardive dyskinesia.

14. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is ballism.

15. The compound for use according to any of the claims 1-10, wherein the hyperkinetic movement disorder is dystonia.

16. The compound for use according to any of the claims 1-15 as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers.

17. The compound for use according to claim 16, wherein the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form.

18. The combination for use according to any of the claims 8-9, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia.


19. The combination for use according to any of the claims 8-9, wherein the hyperkinetic movement disorder is chorea associated to Huntington's disease.

20. The combination for use according to any of the claims 8-9 as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers.

21. The combination for use according to claim 20, wherein the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form.

CLAIMS

1. Use of a compound of formula (IA) or a pharmaceutically acceptable salt thereof



(IA)


in the preparation of a medicament for the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

2. Use according to Claim 1, in which the prophylaxis or treatment comprises administering as a unique active ingredient the compound of formula (IA).

3. Use according to Claim 1 or 2, in which the prophylaxis or treatment comprises administering the compound of formula (IA) in combination therapy with an additional therapeutic agent selected from the group consisting of a compound of formula (IB), a compound of formula (IC), a neuroleptic agent, an anti-glutamatergic agent, a dopamine depleting agent, an acetyl cholinesterase inhibitor, and mixture thereof;


in which:

the compound of formula (IB) is



(IB)

and the compound of formula (IC)



(IC)

4. Use according to Claim 3, in which the combination therapy comprises administering to a subject simultaneously, sequentially or separately the compound of formula (IA) and the additional therapeutic agent.

5. Use according to Claim 3 or 4, in which the additional therapeutic agent is selected from the group consisting of a compound of formula (IB), a compound of formula (IC), amantadine, riluzole, tetrabenazine, reserpine, and donepezil.

6. Use of a combination of a compound of formula (IA) and an additional therapeutic agent as defined in Claim 3, 4 or 5, in the preparation of a medicament for the prophylaxis and/or treatment of a hyperkinetic movement disorder associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia.

7. Use according to any preceding claim, in which the hyperkinetic movement disorder is selected from the group consisting of abdominal dyskinesias, akathisic movements, asynergia, ataxia, athetosis, ballism, chorea, dysmetria, dystonia, hemifacial spasm, hyperekplexia, hypnogenic dyskinesias, jumpy stumps, moving toes and/or fingers, myoclonus, myokymia, myorhythmia, paroxysmal dyskinesias, tics, and tremors.

8. Use according to any preceding claim, in which the hyperkinetic movement disorder is chorea associated to Huntington’s disease, Tourette syndrome, and tardive dyskinesia.

9. Use according to any preceding claim, in which the hyperkinetic movement disorder is chorea associated to Huntington’s disease.

10. Use according to any of Claims 1 to 7, in which the hyperkinetic movement disorder is tics associated to Tourette syndrome and tardive dyskinesia.

11. Use according to any of Claims 1 to 7, in which the hyperkinetic movement disorder is ballism.

12. Use according to any of Claims 1 to 7, in which the hyperkinetic movement disorder is dystonia.

13. Use of a compound according to any preceding claim as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers.

14. Use according to Claim 13, in which the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form.

15. Use according to Claim 6, in which the hyperkinetic movement disorder is chorea associated to Huntington's disease, Tourette syndrome, and tardive dyskinesia.

16. Use according to Claim 6, in which the hyperkinetic movement disorder is chorea associated to Huntington's disease.

17. Use according to Claim 6 as an ingredient of a pharmaceutical composition comprising an effective amount of the compound of formula (IA) or a pharmaceutically acceptable salt thereof, in combination with pharmaceutically acceptable excipients or carriers.

18. Use according to Claim 17, in which the pharmaceutical composition is an oral unit dosage form, intraoral unit dosage form, inhalation dosage form, and topical unit dosage form.